Patient experience data (PED) is gaining ground with regulators
TThe EMA has published a draft reflection paper and the FDA has built out its Patient-Focused Drug Development framework. HTA bodies are less aligned: our review of nine markets found guidance on assessing PED uneven. For manufacturers, this creates uncertainty over which methods decision-makers will accept. Read on to find out how markets compare, which challenges keep coming up, and why your PED strategy matters
Please enter your details in the form on the right to download the full whitepaper
